Glioblastoma are among the most vascularized of all solid tumors and attractive targets for antiangiogenic therapies. Antiangiogenic therapy response assessment in glioblastoma is challenging due to decreased vessel permeability and diminished contrast agent extravasation. Here, we investigated the variability of vascular hysteresis loop (VHL) shapes and the spatial heterogeneity of neovascularization using vascular architecture mapping (VAM) in patients with recurrent glioblastoma during bevacizumab mono-therapy. Responding, non-responding, progressive, and remote-progressive tumor areas were observed. Analysis of VHLs in combination with VAM biomarkers may lead to a new perspective on investigating the spatial heterogeneity of neovascularization in glioblastoma during antiangiogenic therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords